Education
About Us
Working with TipRanks
Follow Us
Akoya Biosciences (AKYA)
NASDAQ:AKYA
AKYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.01 - $4.65
Previous CloseN/A
Volume11.73K
Average Volume (3M)202.99K
Market Cap
$58.31M
Enterprise Value$183.67M
Total Cash (Recent Filing)$11.78M
Total Debt (Recent Filing)$7.96M
Price to Earnings (P/E)―
Beta2.61
Next Earnings
May 20, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding49,836,930
10 Day Avg. Volume152,598
30 Day Avg. Volume202,987
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.04
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market Cap3.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.84
Enterprise Value/Ebitda-4.70
Forecast
1Y Price Target
$2.32Price Target Upside82.68% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Management ExpertiseAKYA's CEO, Brian McKelligon, plans to join the combined company, which is viewed positively given his expertise with AKYA's products and knowledge in oncology.
Merger SynergiesThe merger is expected to yield approximately $40 million in annual cost synergies by the end of 2026.
Stock PerformanceShares of AKYA gained 14% following the news that it reached a definitive agreement to be acquired by Quanterix in an all-stock transaction.
Bears Say
Academic Research FundingNIH funding uncertainty could negatively impact AKYA's academic research business going forward.
Revenue DeclineRevenue decreased about 19% to $21.3 million in 4Q, and the company's full-year 2024 revenue represented a decline of 15.5%.
Shareholder SkepticismThe deal is facing shareholder opposition, valuation concerns, and general market skepticism.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AKYA FAQ
What was Akoya Biosciences’s price range in the past 12 months?
Akoya Biosciences lowest stock price was $1.01 and its highest was $4.65 in the past 12 months.
What is Akoya Biosciences’s market cap?
Akoya Biosciences’s market cap is $58.31M.
When is Akoya Biosciences’s upcoming earnings report date?
Akoya Biosciences’s upcoming earnings report date is May 20, 2025 which is in 25 days.
How were Akoya Biosciences’s earnings last quarter?
Akoya Biosciences released its earnings results on Mar 17, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.163 by -$0.007.
Is Akoya Biosciences overvalued?
According to Wall Street analysts Akoya Biosciences’s price is currently Undervalued.
Does Akoya Biosciences pay dividends?
Akoya Biosciences does not currently pay dividends.
What is Akoya Biosciences’s EPS estimate?
Akoya Biosciences’s EPS estimate is -0.21.
How many shares outstanding does Akoya Biosciences have?
Akoya Biosciences has 49,836,930 shares outstanding.
What happened to Akoya Biosciences’s price movement after its last earnings report?
Akoya Biosciences reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.163. Following the earnings report the stock price went up 3.846%.
Which hedge fund is a major shareholder of Akoya Biosciences?
Currently, no hedge funds are holding shares in AKYA
---
Akoya Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.32 (82.68% Upside)
$2.32 (82.68% Upside)
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.66%
12-Months-Change
Fundamentals
Return on Equity
-180.44%
Trailing 12-Months
Asset Growth
-30.69%
Trailing 12-Months
Company Description
Akoya Biosciences
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
---
AKYA Stock 12 Month Forecast
Average Price Target
$2.32
▲(82.68% Upside)
Technical Analysis
Acumen Pharmaceuticals
―
TScan Therapeutics
―
Invivyd
―
Acrivon Therapeutics, Inc.
―
Adlai Nortye Ltd. Sponsored ADR
―
Best Analysts Covering AKYA
1 Year
1 Year Success Rate
0/16 ratings generated profit
1 Year Average Return
-40.44%
assigned a buy rating 5 months ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -40.44% per trade.
---